• Return to Headlines

Repligen Corp has the Lowest Projected Earnings Growth in the Biotechnology Industry (RGEN, BMRN, AMGN, BIIB, MYGN)

By Shiri Gupta

Below are the three companies in the Biotechnology industry with the lowest projected earnings growth. The growth of earnings per share (current fiscal year estimated vs. last year actual) is important to gauge future profitability and relative value. Higher EPS growth generally justifies higher earnings multiples.

Repligen Corp ranks lowest with a projected earnings growth of 2.3%. Following is Biomarin Pharmac with a projected earnings growth of 3.3%. Amgen Inc ranks third lowest with a projected earnings growth of 9.0%.

Biogen Inc follows with a projected earnings growth of 9.3%, and Myriad Genetics rounds out the bottom five with a projected earnings growth of 13.9%.

SmarTrend is tracking the current trend status for Biogen Inc and will alert subscribers who have BIIB in their portfolio or watchlist when shares have changed trend direction.

Keywords: lowest projected earnings growth repligen corp biomarin pharmac amgen inc biogen inc myriad genetics

Ticker(s): RGEN BMRN AMGN BIIB MYGN